Key terms
About GMDA
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GMDA news
Apr 08
7:31am ET
Xortx Therapeutics appoints Abigail Jenkins to board of directors
Mar 28
2:01am ET
Navigating the Compliance Maze: Gamida Cell’s Approach to Data Privacy and Security Amid Global Regulations
Mar 27
7:08am ET
Gamida Cell commences restructuring process supported by Highbridge
Mar 27
7:02am ET
Gamida Cell reports FY23 EPS (57c), consensus (71c)
Mar 15
4:22pm ET
Gamida Cell Revises Executive Compensation Amid Financial Constraints
Feb 23
8:07am ET
Gamida Cell data presented at 2024 Tandem Meetings of ASTCT, CIBMTR
Jan 29
12:45pm ET
Gamida Cell downgraded to Market Perform from Outperform at JMP Securities
Jan 29
11:15am ET
JMP Securities downgrades Gamida Cell (GMDA) to a Hold
Jan 17
8:05am ET
Gamida Cell to present at tandem meetings of ASTCT, CIBMTR
No recent press releases are available for GMDA
GMDA Financials
Key terms
Ad Feedback
GMDA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GMDA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
